{"disease":{"id":"neoplasms-head-and-neck","name":"neoplasms head and neck"},"drugs":{"marketed":[{"drug_id":"fytic-acid","indication_name":"Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phyliance","generic_name":"fytic acid","company_name":"PDRadiopharma Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06256588","title":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":864,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03942380","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Christian von Buchwald","has_results":false},{"nct_id":"NCT03840421","title":"GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03837808","title":"Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":384,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03485209","title":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06062420","title":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":316,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04128696","title":"Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT03021200","title":"Laser Fluorescence in Cancer Surgical Treatment","phase":"NA","overall_status":"UNKNOWN","enrollment_count":270,"lead_sponsor_name":"Instituto do Cancer do Estado de São Paulo","has_results":false},{"nct_id":"NCT03114501","title":"Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":236,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04222972","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00568490","title":"Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT06662929","title":"Arabic PRO Measures for Head and Neck Cancer Radiotherapy.","phase":"","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"King Saud University","has_results":false},{"nct_id":"NCT06003231","title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04428333","title":"Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":117,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05022667","title":"Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT03356093","title":"Change in Symptom Clusters in HNC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Taipei Medical University","has_results":false},{"nct_id":"NCT07158164","title":"DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT02573493","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04878692","title":"Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies","phase":"NA","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04260126","title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"PDS Biotechnology Corp.","has_results":false},{"nct_id":"NCT02284802","title":"Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy","phase":"NA","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Fauze Maluf Filho","has_results":false},{"nct_id":"NCT03082534","title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT05983133","title":"A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04752215","title":"A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT02296684","title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04634825","title":"Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":62,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04803032","title":"Trident Landmark as a Safe and Easy Method for Facial Nerve Trunk Identification During Superficial Parotidectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Kafrelsheikh University","has_results":false},{"nct_id":"NCT04504669","title":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03332160","title":"A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Tactile Medical","has_results":true},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT04570839","title":"COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT02952989","title":"A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03549494","title":"Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT06110195","title":"Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":42,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT02834247","title":"A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true},{"nct_id":"NCT04525066","title":"Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Ayhman Al Afif","has_results":false},{"nct_id":"NCT04604158","title":"Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Gillian Gresham","has_results":false},{"nct_id":"NCT04879849","title":"A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT00721799","title":"F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"University of Iowa","has_results":true},{"nct_id":"NCT02792322","title":"Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}